38 results on '"Torvinen S"'
Search Results
2. PCN158 PATIENT BURDEN AND COSTS FOR THE TREATMENT OF MULTIPLE MYELOMA IN FINLAND IN 2009-2016, USING MULTIPLE DATA SOURCES: AN ELECTRONIC HOSPITAL DATABASE, MEDICAL CHART REVIEW, AND INTERVIEWS WITH HEALTHCARE PROFESSIONALS
3. PGI16 - THE ECONOMIC BURDEN OF CHRONIC INFLAMMATORY BOWEL DISEASE PATIENTS IN FINLAND
4. PCN119 - SECONDARY CARE RESOURCE UTILIZATION AND COST OF CARE AMONG FINNISH NON-SMALL CELL LUNG CANCER PATIENTS
5. Secondary Care Resource Utilization And Cost Of Care Among Finnish Inflammatory Bowel Disease Patients
6. Productivity Costs Related to Bortezomib And Carfilzomib Administration For Multiple Myeloma In Finland
7. Budesonide + formoterol delivered via Spiromax ® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler ®
8. The Potential to Improve Inhalation Technique in Patients with Asthma Or Copd By Switching From Symbicort® Turbuhaler® (Budesonide + Formoterol) to Duoresp® Spiromax®: Estimated Impact on The Number and Cost of Unscheduled Healthcare Events in Poland
9. Preferences for Dry Powder Inhaler Attributes Among Patients With Asthma and Chronic Obstructive Pulmonary Disease From Five European Countries
10. The Budget Impact Of Duoresp® Spiromax® Compared With Commonly Prescribed Dry Powder Inhalers For The Management Of Asthma And Chronic Obstructive Pulmonary Disease In Italy: Estimated Impact Of Inhalation Technique
11. Evaluation of Inhaler Perception and Preference of Spiromax®, Easyhaler®, And Turbuhaler® Devices (Finhaler)
12. Biosimilars Entry And Price Development In Europe
13. Estimating The Economic Consequences Of An Increased Medication Compliance Due To A Potential Improvement Of The Inhaler Technique With Spiromax® Compared With Turbuhaler® In Moderate To Severe Patients With Copd In Spain
14. Updated Medication Costs From A Real-Life Cost-Effectiveness Evaluation Of Budesonide/Formoterol Maintenance And Reliever Therapy In Asthma Maintenance And Reliever Therapy In Asthma
15. Evaluation of Inhaler Technique Mastery and Handling Errors With Spiromax®, Easyhaler®, And Turbuhaler® Devices (Finhaler)
16. Identification of Factors Involved In Medication Compliance: Incorrect Inhaler Technique of Asthma Treatment Leads to Poor Compliance
17. Comparative Effectiveness Analysis Of Mab In Asthma: The Importance Of Exacerbation Definition
18. Clinical And Economic Burden Of Asthma And Chronic Obstructive Pulmonary Disease (Copd) In Poland: Estimated Impact Of Poor Inhalation Technique With Inhaled Corticosteroid And Long-Acting Beta Agonist Fixed-Dose Combinations
19. The Potential For Improved Inhalation Technique With Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Commonly Prescribed Dry Powder Inhalers For The Management Of Asthma And Chronic Obstructive Pulmonary Disease In Spain: Estimated Impact On Number And Cost Of Unscheduled Healthcare Events
20. The Budget Impact Of An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk: Estimated Impact On Unscheduled Healthcare Costs And Inhaler Satisfaction
21. The Potential Societal Cost Benefits Of Increasing Patient Satisfaction By Using An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk
22. A Budget Impact Analysis To Estimate The Economic Consequences Of An Increase Of Medication Compliance Related To A Potential Improvement Of The Inhalation Technique With Spiromax® Compared With Turbuhaler® In Moderate To Severe Asthmatic Patients In Spain
23. The Importance of Inhaler Devices: An Incorrect Inhaler Technique Leads to Suboptimal Medication Compliance In Patients With Copd
24. Patient’s preferences for dry powder inhaler attributes in Asthma and Chronic Obstructive Pulmonary Disease: a discrete choice experiment
25. THE BUDGET IMPACT OF DUORESP® SPIROMAX® (BUDESONIDE + FORMOTEROL FUMARATE DIHYDRATE) COMPARED WITH COMMONLY PRESCRIBED DRY POWDER INHALERS FOR THE MANAGEMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UNITED KINGDOM: IMPACT OF INHALATION TECHNIQUE
26. The Potential Societal Cost Benefits of Improved Inhalation Technique With Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbuhaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in Sweden
27. Identification of Dry Powder Inhaler Attributes, and their Relative Importance to Asthma and Chronic Obstructive Pulmonary Disease Patients, to Inform a Discrete Choice Experiment
28. The Budget Impact of Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbohaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in the United Kingdom: Impact on Health Care Costs and Inhalation Technique
29. Clinical And Economic Burden Of Asthma And Chronic Obstructive Pulmonary Disease In The Uk: Impact Of Critical Inhaler Errors With Inhaled Corticosteroid + Long-Acting Beta Agonist Fixed-Dose Combinations
30. PIN45 Health Economic Impact of Infant Vaccination Program With PHiD-CV and PCV13 Using New Efficacy/Effectiveness Data. Example of Finland
31. Effects of diet-induced obesity and voluntary wheel running on bone mechanical properties from male young C57/6J mice
32. Effects of diet-induced obesity and voluntary wheel running on the axial and peripheral skeleton microstructure in mice
33. PCN21 COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FORWOMEN WITH HER2+ METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND
34. PRS5 REDUCTION IN TOTAL TREATMENT COSTS THROUGH IMPROVED PHARMACEUTICAL TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES
35. PIN43 ADAPTATION OF A HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER IN A WELL FUNCTIONING POPULATION-BASED SCREENING SYSTEM—A MODEL CALIBRATION TO FINLAND
36. PIN42 EVALUATING THE CLINICAL EFFECTS AND THE COST-EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCER VACCINATION WITHIN AN ORGANISED POPULATION-BASED SCREENING SETTING—CASE FINLAND
37. PHP18 PRICES OF GENERIC DRUGS IN FINLAND VS. EUROPE
38. Integrating computer aided quality assurance in flexible engineering and production processes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.